NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
The clonoSEQ® Watch Registry
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Multiple Myeloma Patients
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
NCT03549442: Phase 1 - CART-BCMA +/- huCART19 as Consolidation High Risk MM
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma